Abstract
Cellular uptake of hydrophilic antifolates proceeds via the reduced folate carrier whereas lipophilic antifolates enter cells by diffusion. Recently we have shown that transfectant cells overexpressing the mutant G482 ABCG2 displayed 120–6,250-fold resistance to hydrophilic antifolates than untransfected cells upon 4 h drug exposure, but lost almost all their antifolate resistance upon 72 h drug exposure (Shafran et al. in Cancer Res 65:8414–8422, 2005). Here we explored the ability of the wild type (WT) R482—as well as the mutant G482—and T482 ABCG2 to confer resistance to lipophilic antifolate inhibitors of dihydrofolate reductase (trimetrexate, piritrexim, metoprine and pyrimethamine) and thymidylate synthase (AG337, AG377 and AG331). Lipophilic antifolate resistance was determined using growth inhibition assays upon 72 h drug exposure. Cells overexpressing these mutant efflux transporters displayed up to 106-fold resistance to lipophilic antifolates relative to untransfected cells; this resistance was reversed by the specific and potent ABCG2 efflux inhibitor Ko143. In contrast, cells overexpressing the WT R482 ABCG2 exhibited either no or only a low-level of lipophilic antifolate resistance. These results provide the first evidence that overexpression of the mutant G482- and T482 but not the WT R482 ABCG2 confers a high-level of resistance to lipophilic antifolates. The high membrane partitioning of lipophilic antifolates along with the large confinement of ABCG2 to the plasma membrane suggest that these mutant ABCG2 transporters may possibly recognize and extrude lipophilic antifolates from the lipid bilayer. The potential implications to cancer chemotherapy as well as the mechanism of anticancer drug extrusion by these mutant exporters are discussed.
Similar content being viewed by others
Abbreviations
- ABC:
-
ATP-binding cassette protein
- BCRP:
-
Breast cancer resistance protein
- MRP:
-
Multidrug resistance protein
- Pgp:
-
P-glycoprotein
- DHFR:
-
Dihydrofolate reductase
- TS:
-
Thymidylate synthase
References
Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592
Dean M, Harmon Y, Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007–1017
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468–7485
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654
Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7535–7552
Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21–53
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670
Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337–5339
Miyake K, Mickley L, Litman T, Zhan Z, Robey RW, Christensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8–13
Sarkadi B, Ozvegy-Laczka O, Nemet K, Varadi A (2004) ABCG2—a transporter for all seasons. FEBS Lett 567:116–120
Staud F, Pavek P (2005) Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37:720–725
Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, Sugimoto Y (2002) Dominant-negative inhibition of breast cancer resistance protein as a drug efflux pump through the inhibition of S–S dependent dimerization. Int J Cancer 97:626–630
Xu J, Liu Y, Yang Y, Bates SE, Zhang JT (2004) Characterization of oligomeric human half-ABCC transporter ATP-binding cassette G2. J Biol Chem 279:19781–19789
Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, Bates SE (2004) Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43:9448–9456
Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers high level resistance to hydrophilic antifolates. Cancer Res 65:8414–8422
Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Kooman GJ, Schinkel AH (2002) Potent and specific inhibition of breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417–425
Duch DS, Edelstein MP, Bowers SW, Nichol CA (1982) Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res 42:3987–3994
Fry DW, Besserer JA (1988) Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 48:6986–6991
Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11:5–14
Assaraf YG, Molina A, Schimke RT (1989) Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug resistance phenotype. J Natl Cancer Inst 81:290–294
Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG (2002) Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cells. Biochem J 367:741–750
Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG (2003) Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 103:587–599
Purcell WT, Ettinger DS (2003) Novel antifolate drugs. Curr Oncol Rep 5:114–125
Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52:S80–S89
Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971–1978
Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, Jansen G (1995) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459–471
Taylor CW, Dalton WS, Parrish PR et al (1991) Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF-7 human breast cancer cell line. Br J Cancer 63:923–929
Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG (2004) Folate deprivation results in the loss of breast cancer resistance protein (ABCG2) expression: a role for BCRP in cellular folate homeostasis. J Biol Chem 279:25527–25534
Hansch C, Hoekman D, Leo A, Zhang L, Li P (1995) The expanding role of quantitative structure–activity relationships (QSAR) in toxicology. Toxicol Lett 79:45–53
Borgnia MJ, Eytan GD, Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163–3171
Assaraf YG, Molina A, Schimke RT (1989) Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. J Biol Chem 264:18326–18334
Volk EL, Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538–5543
Chen Z-S, Robey RW, Belinsky MG, Schvaveleva I, Ren XO, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates and 17beta-estradiol 17-(beta-d-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048–4054
Gombar VK, Polli JW, Humphreys JW, Wring AW, Serabjit-Singh CS (2004) Predicting P-glycoprotein substrates by a quantitative structure–activity relationship model. J Pharm Sci 93:957–968
Eytan GD, Regev R, Oren G, Hurwitz C, Assaraf YG (1997) Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 248:104–112
Acknowledgments
Grant support: The Fred Wyszkowski Cancer Research Fund, Israel Cancer Association and the Star Foundation (to YGA) as well as the Dutch Arthritis Association (NRF 03-40I to GJ). We thank Dr S.E. Bates (Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD) for the HEK293 transfectants overexpressing the R482-, G482- and T482 ABCG2. We extend our gratitude to Dr G.L. Scheffer and Prof. R.J. Scheper (Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands) for the BXP-53 monoclonal antibody, Prof. A.H. Schinkel for the kind gift of Ko143 as well as Prof. S.J. Karlish (Department of Biological Chemistry, The Weizmann Institute of Science, Rehovoth, Israel) for the polyclonal antiserum against Na+–K+-ATPase.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bram, E., Ifergan, I., Shafran, A. et al. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol 58, 826–834 (2006). https://doi.org/10.1007/s00280-006-0230-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-006-0230-9